GlassScriptPhysician profile
Tina Hedayat
NPI 1477841492
$3,514.55
in general payments reported to CMS, 2019-2025
24 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.93 · 2021: $919 · 2022: $552 · 2023: $670 · 2024: $521 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,255.07 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $441.97 | 2020-2025 | Zilbrysq, Fintepla, Briviact |
| Alexion Pharmaceuticals, INC. | $235.24 | 2023-2025 | Ultomiris, Soliris |
| Abbvie INC. | $227.53 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $173.46 | 2023-2025 | Ingrezza, Ongentys |
| Csl Behring | $135.01 | 2023-2025 | Hizentra |
| Lilly USA, LLC | $134.03 | 2022-2023 | Reyvow, Emgality |
| Treace Medical Concepts, INC. | $116.64 | 2024 | |
| Eisai INC. | $116.32 | 2023-2025 | |
| Kyowa Kirin, INC. | $113.05 | 2023 | Nourianz |
| Genentech USA, INC. | $106.00 | 2022-2024 | Ocrevus, Enspryng |
| Amgen INC. | $98.07 | 2024-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $51.87 | 2025 | Austedo Xr |
| Neurelis, INC. | $47.94 | 2022-2023 | Valtoco |
| Acadia Pharmaceuticals INC | $45.84 | 2023 | Nuplazid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $33.67 | 2023 | Vyvgart |
| Pfizer INC. | $32.10 | 2024 | |
| Horizon Therapeutics Plc | $27.47 | 2023 | Uplizna |
| Biogen, INC. | $26.73 | 2025 | Tysabri, Vumerity |
| Ceribell, INC. | $22.36 | 2021 | |
| Sk Life Science, INC. | $20.07 | 2025 | |
| Grifols USA, LLC | $19.02 | 2024 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $18.93 | 2025 | Rytary |
| Kci USA, INC. | $16.16 | 2023 | V.A.C. Veraflo, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Hedayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.